The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study

Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determ...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ganghee Chae, Aram Choi, Soyeoun Lim, Sooneun Park, Seungjun Lee, Youngick Ahn, Jinhyoung Kim, Seungwon Ra, Yangjin Jegal, Jongjoon Ahn, Eunji Park, Jaebum Jun, Woonjung Kwon, Taehoon Lee
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2022-03-01
סדרה:	Tropical Medicine and Infectious Disease
נושאים:	regdanvimab remdesivir COVID-19 severe
גישה מקוונת:	https://www.mdpi.com/2414-6366/7/3/51
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!